TABLE 4.
Cross-resistance of virus isolates with defined amino acid changes
| Virus isolate or amino acid change | EC50 (μM)a
|
||||
|---|---|---|---|---|---|
| Calanolide A | Costatolide | Dihydrocostatolide | Nevirapine | AZT | |
| NL4-3 | 0.1 | 0.2 | 0.5 | 0.02 | 0.001 |
| L74V | 0.1 | 0.2 | 0.6 | 0.02 | 0.005 |
| A98G | 0.2 | 0.3 | 0.2 | 0.2 | 0.01 |
| L100I | 22.0 | 5.0 | >20 | 0.1 | 0.003 |
| K101E | 1.7 | 2.9 | 3.5 | 0.3 | 0.002 |
| K103N | 1.7 | 1.2 | 3.8 | >2 | 0.004 |
| V106I | 0.2 | 0.2 | 0.8 | >2 | 0.003 |
| V108I | 0.3 | 0.2 | 1.2 | 0.06 | 0.008 |
| T139I | 1.7 | 11.9 | 2.9 | 0.002 | 0.003 |
| V179D | 0.05 | 0.1 | 0.4 | 0.03 | 0.003 |
| Y181C | 0.02 | 0.02 | <0.06 | 1.3 | 0.01 |
| Y188C | 1.7 | 1.7 | 1.0 | 3.2 | 0.006 |
| 4 × AZT | 0.2 | 0.2 | 0.3 | 0.02 | 0.8 |
| 4 × AZT + Y181C | 0.01 | 0.01 | <0.06 | 0.8 | 0.04 |
| 4 × AZT + L100I | 1.5 | 3.0 | >20 | 0.03 | 0.02 |
a
EC50s are the means for a minimum of two replicate evaluations. The reproducibilities of the EC50s obtained between replicate experiments in this highly optimized anti-HIV assay have been determined to be such that the standard errors averaged less than 10% of the respective mean value.